Oncolytic virus platform to treat cancers with myxoma virus
US-11117934-B2 · Sep 14, 2021 · US
Methods of treating cancer with TNF expressing myxoma virus
US12257278B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12257278-B2 |
| Application number | US-201917259849-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 12, 2019 |
| Priority date | Jul 13, 2018 |
| Publication date | Mar 25, 2025 |
| Grant date | Mar 25, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein, in certain embodiments, is a method of inhibiting or treating a cancer with use of a TNF expressing myxoma virus. Also disclosed herein are methods of inhibiting or treating a cancer with use of a mononuclear peripheral blood cells and/or a bone marrow cells treated with a TNF-expressing myxoma virus. Some aspects relate to engineered myxoma virus and pharmaceutical compositions for use with one or more of the methods described herein.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a myxoma virus (MYXV) and a pharmaceutically-acceptable excipient, wherein the MYXV is engineered to express a tumor necrosis factor (TNF) protein, wherein a gene encoding the TNF protein is inserted between M134 gene and M136 gene within the MYXV genome. 2. The pharmaceutical composition of claim 1 , wherein the TNF protein is a TNF alpha protein. 3. The pharmaceutical composition of claim 1 , wherein the TNF protein is a cell surface expressed TNF protein. 4. The pharmaceutical composition of claim 1 , wherein the TNF protein is secreted by cells infected by the MYXV. 5. The pharmaceutical composition of claim 1 , wherein the TNF protein is a human TNF protein. 6. The pharmaceutical composition of claim 1 , wherein the MYXV is a genetically modified Laussane strain MYXV. 7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for systemic administration. 8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for local administration. 9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for parenteral administration. 10. The pharmaceutical composition of claim 1 , wherein the MYXV is capable of directly killing cancer cells infected by the MYXV and eliciting off-target killing of uninfected cancer cells. 11. The pharmaceutical composition of claim 10 , wherein the MYXV exhibits enhanced off-target killing of uninfected cancer cells as compared to a MYXV that is not engineered to express the TNF protein. 12. A composition comprising peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof treated ex vivo by a myxoma virus (MYXV) engineered to express a tumor necrosis factor (TNF) protein, wherein a gene encoding the TNF protein is inserted between M134 gene and M136 gene within the MYXV genome. 13. The composition of claim 12 , wherein the MYXV comprises a modification within or adjacent to one or more genes associated with rabbit cell tropism. 14. The composition of claim 12 , wherein the MYXV comprises a modification of M135R that impairs function of the M135R. 15. A method of inhibiting or treating a cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a myxoma virus (MYXV) and a pharmaceutically-acceptable excipient, wherein the MYXV is engineered to express a tumor necrosis factor (TNF) protein, wherein a gene encoding the TNF protein is inserted between M134 gene and M136 gene within the MYXV genome.
Assignees
Inventors
Classifications
Tumour necrosis factor [TNF] · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12257278B2 cover?
- Disclosed herein, in certain embodiments, is a method of inhibiting or treating a cancer with use of a TNF expressing myxoma virus. Also disclosed herein are methods of inhibiting or treating a cancer with use of a mononuclear peripheral blood cells and/or a bone marrow cells treated with a TNF-expressing myxoma virus. Some aspects relate to engineered myxoma virus and pharmaceutical compositio…
- Who is the assignee on this patent?
- Univ Arizona State
- What technology area does this patent fall under?
- Primary CPC classification A61K38/191. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).